Evidence map›Paper›PMID 26496451›Full record

ArticleCritical care medicine2016

A Selective V(1A) Receptor Agonist, Selepressin, Is Superior to Arginine Vasopressin and to Norepinephrine in Ovine Septic Shock.

Xinrong He, Fuhong Su, Fabio Silvio Taccone, Régent Laporte, Anne Louise Kjølbye, Jing Zhang, Keliang Xie, Mouhamed Djahoum Moussa, Torsten Michael Reinheimer, Jean-Louis Vincent

Open access · greenAbstract readComparative Study
In one paragraph

Article in Critical care medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Selepressin, a novel selective vasopressin VCritical care (London, England) · 2017
    Trial
  4. Hepatorenal Syndrome-Novel Insights into Diagnostics and Treatment.International journal of molecular sciences · 2023
    Review
  5. Article
  6. Angiotensin 1-7 in an experimental septic shock model.Critical care (London, England) · 2023
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Fluid Resuscitation for Refractory Hypotension.Frontiers in veterinary science · 2021
    Review
  12. Article
  13. Review
  14. Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use.Journal of cardiovascular pharmacology · 2020
    Review
  15. Vasopressors in septic shock: which, when, and how much?Annals of translational medicine · 2020
    Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 4 countries.

Xinrong He1Department of Intensive Care, Erasme Hospital, Université libre de Bruxelles, Brussels, Belgium.2Department of Intensive Care, Sun Yat-sen University Cancer Center, Guangzhou, China.3Clinical & Non-Clinical R&D, Ferring Research Institute, San Diego, CA.4Clinical & Non-Clinical R&D, Ferring Pharmaceuticals A/S, Copenhagen, Denmark.5Department of Biochemistry and Nutrition, Université Libre de Bruxelles, Brussels, Belgium.
Fuhong Su
Fabio Silvio Taccone
Régent Laporte
Anne Louise Kjølbye
Jing Zhang
Keliang Xie
Mouhamed Djahoum Moussa
Torsten Michael Reinheimer
Jean-Louis Vincent
Université Libre de Bruxelles · BEFerring Pharmaceuticals (Denmark) · DKInstitute of Clinical Research · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveSelective vasopressin V(1A) receptor agonists may have advantages over arginine vasopressin in the treatment of septic shock. We compared the effects of selepressin, a selective V(1A) receptor agonist, arginine vasopressin, and norepinephrine on hemodynamics, organ function, and survival in an ovine septic shock model.

designRandomized animal study.

settingUniversity hospital animal research laboratory. SUBJECTS: Forty-six adult female sheep.

interventionsFecal peritonitis was induced in the anesthetized, mechanically ventilated, fluid-resuscitated sheep, and they were randomized in two successive phases. Three late-intervention groups (each n = 6) received IV selepressin (1 pmol/kg/min), arginine vasopressin (0.25 pmol [0.1 mU]/kg/min), or norepinephrine (3 nmol [0.5 μg]/kg/min) when mean arterial pressure remained less than 70 mm Hg despite fluid challenge; study drugs were thereafter titrated to keep mean arterial pressure at 70-80 mm Hg. Three early-intervention groups (each n = 7) received selepressin, arginine vasopressin, or norepinephrine at the same initial infusion rates as for the late intervention, but already when mean arterial pressure had decreased by 10% from baseline; doses were then titrated as for the late intervention. A control group (n = 7) received saline. All animals were observed until death or for a maximum of 30 hours. MEASUREMENTS AND MAIN

resultsIn addition to hemodynamic and organ function assessment, plasma interleukin-6 and nitrite/nitrate levels were measured. In the late-intervention groups, selepressin delayed the decrease in mean arterial pressure and was associated with lower lung wet/dry weight ratios than in the other two groups. In the early-intervention groups, selepressin maintained mean arterial pressure and cardiac index better than arginine vasopressin or norepinephrine, slowed the increase in blood lactate levels, and was associated with less lung edema, lower cumulative fluid balance, and lower interleukin-6 and nitrite/nitrate levels. Selepressin-treated animals survived longer than the other animals.

conclusionsIn this clinically relevant model, selepressin, a selective V(1A) receptor agonist, was superior to arginine vasopressin and to norepinephrine in the treatment of septic shock, especially when administered early.

Indexed as

AnimalsArginine VasopressinFemaleNorepinephrineRandom AllocationReceptors, VasopressinSheepSheep DiseasesShock, SepticVasoconstrictor AgentsVasopressinsArginine VasopressinNorepinephrineReceptors, VasopressinVasoconstrictor Agentsvasopressin, Phe(2)-Ile(3)-Hgn(4)-Orn(iPr)(8)-Vasopressins

Identifiers

PMID26496451
PMCPMC4684247
OpenAlexW2173724449

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.